These hyper-responsive genes were further induced when Btz was combined with the PDI inhibitor LTI6426 (Figure S2A), which is highly synergistic with Btz in CTCL (Figure S2B) and a wide variety of other tumor types [31,37,38]. This evidence concerns the gene CASC3 and primary cutaneous T-cell non-Hodgkin lymphoma.